US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Anti-Pandemic Concept

1,801.59

-33.3528-1.82%

Number of Gainers:2

Number of Losers:17

Number of Flat:- -

PE:- -

High:1,831.29

Open:1,830.64

Low:1,800.68

Close:1,834.82

Volume:33.30M

Turnover:2.48B

Market Cap:1.46T

Float Cap:1.43T

Loading ...

Top Premarket Gainers

MT Newswires Live

Ocugen CEO Musunuri Moderates H.C. Wainwright Biotech on Tap Panel

Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer

THOMSON REUTERS

AstraZeneca Dips Toes in Emerging Class of Cancer Drugs

Pfizer Gets Tax Penalty of 12.6 Million Rupees

Hutchmed Lung-Cancer Fighting Drug Submitted to FDA for Approval

MT Newswires Live

SoftOx Names Dr. Bruce Montgomery to Chair Clinical Advisory Board

AstraZeneca Broadens Oncology Portfolio Through Summit Deal

Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Moderna (MRNA)

Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit

How Investors May Respond To Pfizer (PFE) ESMO Cancer Data Showcase

Simply Wall St.

Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC

Stocks to Watch: Summit Therapeutics, Sangoma, Navitas

Nanoviricides Q4 EPS $(0.10), Inline

Benzinga Earnings

Summit Therapeutics, AstraZeneca enter clinical collaboration agreement

Novavax Inc. Stock Outperforms Competitors on Strong Trading Day

BioNTech CEO Uğur Şahin Disposes of USD 6,090,748 in Common Shares

NanoViricides FY26 Net Loss Narrows 13% to $8.22 Million; Revenue Remains no Revenue

Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit

Market Chatter: BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/BK4568/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK4568","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","market":"US","secType":"PLATE","nameCN":"Anti-Pandemic Concept","latestPrice":1801.4685,"timestamp":1791475533669,"preClose":1834.8213,"halted":0,"volume":33304498,"delay":0,"changeRate":-0.018178,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Trading","change":-33.352783,"latestTime":"10-08 12:05:33 EDT","open":1830.6383,"high":1831.2853,"low":1800.6757,"amount":2480249356.336037,"amplitude":0.016683,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1791489600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"pbRate":4.731558,"peRate":45.863803,"turnoverRate":0.0024,"increases":2,"decrements":17,"flats":0,"marketCap":1464489660673.5,"floatMarketCap":1430013236971},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK4568\",,,,,undefined,":{"symbol":"BK4568","high":1831.2853,"amplitude":0.016683,"preClose":1834.8213,"low":1800.6757,"pbRate":"4.731558","latestPrice":1801.5872,"volume":33297979,"delay":0,"open":1830.6383,"prevYearClose":1637.1339,"prevWeekClose":1811.1105,"prevMonthClose":1862.664,"prevQuarterClose":1862.664,"fiveDayClose":1824.9855,"twentyDayClose":1831.6982,"sixtyDayClose":1680.0864,"secType":"PLATE","market":"US","turnoverRate":0.0024,"peRate":45.863803,"marketCap":1464715677953.5,"floatMarketCap":1430233691883,"timestamp":1791475528914,"nameCN":"Anti-Pandemic Concept"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK4568\",,,,undefined,":{"bkCode":"BK4568","up":2,"down":17,"flat":0},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK4568\",pageSize:20,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2671169572","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2671169572","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671169572?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:12","pubTimestamp":1790680360,"startTime":"0","endTime":"0","summary":"Summit Therapeutics  shares were up more than 23% pre-bell Tuesday after AstraZeneca  agreed to invest $2 billion in convertible preferred shares in Summit, along with a nonbinding clinical collaboration focused on ivonescimab and sonesitatug vedotin.Navitas Semiconductor  stock was 12% higher after the company said late Monday it was awarded the Accelerated, Large-Area, 10 kV SiC IGBT program to develop next-generation 10-kilovolt silicon carbide power semiconductor technology.Q32 Bio  shares were up 9% after Jefferies initiated the company's coverage at buy with a $29 price target.Deep Fission  stock was 8.7% higher, partially reversing the 13% loss at Monday's close.Armada Acquisition Corp. II  shares were up over 8% after a marginal retreat at the prior close.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0128525929.USD","LU0310800379.SGD","LU1267930573.SGD","LU2488822045.USD","XRPN","LU2468319806.SGD","LU2462157665.USD","LU0058720904.USD","LU0289739699.SGD","LU0320765992.SGD","LU2236285917.USD","SMMT","BK4585","BK4588","LU2237443895.HKD","LU2237443978.SGD","AZNH","LU0029864427.USD","LU2456880835.USD","IE00B3T34201.USD","QTTB","BK4105","LU0109394709.USD","LU0889565916.HKD","LU2237443549.SGD","BK4007","BK4139","BK4568","LU1829250122.USD","LU2089984988.USD","FISN","NVTX","LU0708994859.HKD","LU0432979614.USD","LU2237443622.USD","LU2417539215.USD","BK4141","AZN","LU2237443382.USD","NVTS","LU2237443465.HKD","NVTC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671168012","title":"Ocugen CEO Musunuri Moderates H.C. Wainwright Biotech on Tap Panel","url":"https://stock-news.laohu8.com/highlight/detail?id=2671168012","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671168012?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:04","pubTimestamp":1790679846,"startTime":"0","endTime":"0","summary":"Ocugen CEO Musunuri moderates H.C. Wainwright Biotech on Tap panelOcugen will join two October investor and industry conferences, with CEO Shankar Musunuri slated for panel discussions.Oct. 1, 2026: M","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDL40KhrK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2W23.USD","IE00BQXX3C00.GBP","SG9999014013.SGD","IE00BQXX3D17.EUR","IE00BN0W2T93.GBP","IE00B3QW5Z07.USD","LU2095319765.USD","IE00BQXX3F31.USD","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD","BK4568","LU2210149790.SGD","NDAQ","OCGN","BK4112","LU0314104364.USD","BK4563","IE00BKPKM429.USD","BK4588","IE00BGHQF748.EUR","SG9999014039.USD","IE00BN0W2V16.EUR","SG9999014021.USD","BCDF","LU2210150020.SGD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671157692","title":"Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer","url":"https://stock-news.laohu8.com/highlight/detail?id=2671157692","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671157692?lang=en_us&edition=fundamental","pubTime":"2026-09-29 19:00","pubTimestamp":1790679601,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nTUA42HKSY:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BBT3K403.USD","BK4550","IE00B19Z3581.USD","IE000M9KFDE8.USD","LU0306806265.USD","LU0306807586.USD","SG9999001176.SGD","LU2596442595.SGD","NRIX","LU0985481810.HKD","SG9999002224.SGD","BK4534","BK4139","BK4599","LU0321505439.SGD","LU1894683264.USD","SG9999003800.SGD","IE00B19Z3B42.SGD","LU0058720904.USD","LU1066053197.SGD","LU0170899867.USD","LU1057294990.SGD","SG9999013999.USD","BK4581","LU0225284248.USD","LU1066051498.USD","LU0456855351.SGD","BK4007","SGXZ57979304.SGD","IE00BLSP4452.SGD","BK4568","LU0122379950.USD","LU0225771236.USD","BK4533","LU1883839398.USD","IE0002270589.USD","IE00BLSP4239.USD","SG9999011175.SGD","IE00B3T34201.USD","BK4588","BK4585","LU0234572021.USD","LU0868494617.USD","LU0289739699.SGD","PFE","SG9999001176.USD","SG9999002232.USD","OZEM","LU0321505868.SGD","BK4592","LU1023059063.AUD","LU1894683348.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671297054","title":"AstraZeneca Dips Toes in Emerging Class of Cancer Drugs","url":"https://stock-news.laohu8.com/highlight/detail?id=2671297054","media":"Dow Jones","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671297054?lang=en_us&edition=fundamental","pubTime":"2026-09-29 17:15","pubTimestamp":1790673300,"startTime":"0","endTime":"0","summary":"0914 GMT - AstraZeneca's investment in Summit Therapeutics gives the U.K. drugmaker skin in the game of an emerging class of cancer drugs, UBS analysts say in a research note. Miami-based Summit is developing a cancer drug called ivonescimab that blocks two proteins known as PD-1 and VEGF. Evidence is emerging that this drug class might be superior to Merck's blockbuster medicine Keytruda and recent data also point to potential for combinations with antibody-drug conjugates, according to UBS. AstraZeneca has an extensive antibody-drug-conjugate portfolio and the Summit deal allows it to generate data across multiple tumor types, the analysts say. \"If the PD-1/VEGF class does become the new standard of care in various cancers, it will be important to have such combination data,\" they add. AstraZeneca shares rise 1.9%.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443549.SGD","LU0320765992.SGD","LU2236285917.USD","AZN","LU0432979614.USD","LU2237443465.HKD","LU2456880835.USD","BK4007","LU0889565916.HKD","LU0708994859.HKD","BK4585","LU0128525929.USD","BK4568","LU1267930573.SGD","LU2237443382.USD","LU0310800379.SGD","LU2237443622.USD","AZNH","LU0058720904.USD","LU0029864427.USD","LU2237443978.SGD","SMMT","LU2462157665.USD","BK4588","LU0289739699.SGD","IE00B3T34201.USD","LU2089984988.USD","LU2237443895.HKD","LU2468319806.SGD","LU2488822045.USD","LU2417539215.USD","LU0109394709.USD","LU1829250122.USD","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671429782","title":"Pfizer Gets Tax Penalty of 12.6 Million Rupees","url":"https://stock-news.laohu8.com/highlight/detail?id=2671429782","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671429782?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:51","pubTimestamp":1790671866,"startTime":"0","endTime":"0","summary":"Sept 29 (Reuters) - Pfizer Ltd::*PFIZER LTD - GETS TAX PENALTY OF 12.6 MILLION RUPEES((Reuters Investor Briefs; email: reutersinvestor.briefs@thomsonreuters.com))Source Date/Time = 29-SEP-202608:38:00 GMT","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nRSD2TdC85:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4592","BK4588","IE00BLSP4452.SGD","BK4534","BK4550","LU0122379950.USD","LU0456855351.SGD","IE000M9KFDE8.USD","BK4007","SG9999013999.USD","SG9999003800.SGD","SG9999011175.SGD","BK4581","LU1894683264.USD","LU0234572021.USD","LU0985481810.HKD","LU1066051498.USD","SG9999002232.USD","LU0225771236.USD","SGXZ57979304.SGD","BK4599","SG9999002224.SGD","LU0058720904.USD","BK4585","LU1894683348.USD","LU1057294990.SGD","LU1066053197.SGD","LU0868494617.USD","LU0321505439.SGD","LU1883839398.USD","BK4568","OZEM","LU0306806265.USD","IE00BLSP4239.USD","SG9999001176.USD","LU2596442595.SGD","IE0002270589.USD","IE00BBT3K403.USD","LU0306807586.USD","IE00B19Z3581.USD","BK4533","LU0289739699.SGD","LU0321505868.SGD","PFE","IE00B19Z3B42.SGD","LU1023059063.AUD","LU0225284248.USD","SG9999001176.SGD","LU0170899867.USD","IE00B3T34201.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671292587","title":"Hutchmed Lung-Cancer Fighting Drug Submitted to FDA for Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=2671292587","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671292587?lang=en_us&edition=fundamental","pubTime":"2026-09-29 16:26","pubTimestamp":1790670412,"startTime":"0","endTime":"0","summary":"HUTCHMED said Tuesday that partner AstraZeneca  has submitted a New Drug Application to the US Food and Drug Administration for the lung-cancer fighting drugs Orpathys plus Tagrisso.The drug combination treats metastatic non-small cell lung cancers, the tumors of which have over-expression or amplification of proteins on their surfaces, in patients who had disease progression on or after an epidermal growth factor receptor tyrosine kinase inhibitor therapy, said Hutchmed.The drug combination is an oral, biomarker-directed, chemotherapy-free treatment for non-small cell lung cancers, the validity of which is supported by Saffron, a completed global phase III trial, said Hutchmed.The Saffron trial showed the drug combination demonstrated a statistically significant and clinically meaningful improvement in both progression-free survival and overall survival versus doublet platinum-based chemotherapy in patients who progressed on treatment with Tagrisso alone, said Hutchmed.The Orpathys pl","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU2089984988.USD","LU2237443978.SGD","LABU","LU2456880835.USD","LU2462157665.USD","LU0128525929.USD","LU2237443622.USD","LU0889565916.HKD","LU1829250122.USD","HCM","LU0320765992.SGD","LU2237443549.SGD","LU2417539215.USD","LU2468319806.SGD","IE00B3T34201.USD","LU0289739699.SGD","BK4531","LU0310800379.SGD","AZN","LU0058720904.USD","BK4585","BK4007","LU0432979614.USD","AZNH","LU2237443382.USD","BK4568","LU2237443465.HKD","LU1267930573.SGD","LU2236285917.USD","BK4588","LU0109394709.USD","LU2237443895.HKD","LU0708994859.HKD","LU0029864427.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671329926","title":"SoftOx Names Dr. Bruce Montgomery to Chair Clinical Advisory Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2671329926","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671329926?lang=en_us&edition=fundamental","pubTime":"2026-09-29 15:23","pubTimestamp":1790666588,"startTime":"0","endTime":"0","summary":"SoftOx names Dr. Bruce Montgomery to chair Clinical Advisory BoardSoftOx appointed Dr. A. Bruce Montgomery to establish and chair its Clinical Advisory Board ahead of a planned Phase 2b SIS study.Boar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260929:nNDLbDg5Mx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0965509283.SGD","LU0823416689.USD","SG9999015978.USD","LU1934455194.USD","BK4568","LU1571399168.USD","IE00B7SZLL34.SGD","LU1839511570.USD","LU1934455863.HKD","LU1066051498.USD","BMED","LU2357627491.SGD","BIB","BK4578","IE00BZ1G4Q59.USD","LU0965509101.SGD","BK4585","BK4588","LU1778281490.HKD","LU0859254822.USD","IBB","LU2112291526.USD","LU1057294990.SGD","LU1934455277.USD","LU0289739699.SGD","LU1674673428.USD","IE00B19Z3B42.SGD","LU1061106388.HKD","IE00BSNM7G36.USD","LU0882574055.USD","TMED","IE0002270589.USD","BK4566","LU0965509010.AUD","LU1066053197.SGD","IBBQ","GILD","LU0058720904.USD","LU0320765992.SGD","BK4550","BK4583","LU0122379950.USD","TBXU","BK4139","SG9999015986.USD","LU0234570918.USD","IE00B3T34201.USD","LU2089984988.USD","BBH","MEDI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671529344","title":"AstraZeneca Broadens Oncology Portfolio Through Summit Deal","url":"https://stock-news.laohu8.com/highlight/detail?id=2671529344","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671529344?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:49","pubTimestamp":1790660940,"startTime":"0","endTime":"0","summary":"0548 GMT - AstraZeneca's agreement with Summit Therapeutics will help the U.K. drugmaker broaden its immuno-oncology portfolio without going all-in, RBC Capital Markets analysts say in a research note. AstraZeneca is investing $2 billion in the Miami-based biotech and entering into a research collaboration centered on ivonescimab, Summit's experimental cancer drug that blocks two proteins--called PD-1 and VEGF--that help tumors grow and evade the immune system. AstraZeneca's investments in this space lacked a so-called PD-1xVEGF asset like ivonescimab, RBC says. Each company retains its development and commercial rights for their assets, which likely signals AstraZeneca believes its own approaches are superior to PD-1xVEGF, the analysts say. Nevertheless, the deal leaves the door open for a potential expansion with Summit in the future, they add.","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZNH","LU2237443382.USD","LU2488822045.USD","AZN","LU2456880835.USD","LU2237443622.USD","LU0320765992.SGD","LU0310800379.SGD","BK4568","LU2468319806.SGD","BK4007","LU1267930573.SGD","LU0109394709.USD","SMMT","LU2089984988.USD","LU0289739699.SGD","IE00B3T34201.USD","LU0128525929.USD","LU2237443895.HKD","LU0432979614.USD","BK4585","LU2237443978.SGD","LU2462157665.USD","LU2237443549.SGD","LU0708994859.HKD","LU2236285917.USD","LU0029864427.USD","LU1829250122.USD","BK4139","LU0889565916.HKD","LU2417539215.USD","BK4588","LU0058720904.USD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671829804","title":"Analysts Offer Insights on Healthcare Companies: Inventiva (IVA) and Moderna (MRNA)","url":"https://stock-news.laohu8.com/highlight/detail?id=2671829804","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671829804?lang=en_us&edition=fundamental","pubTime":"2026-09-29 13:00","pubTimestamp":1790658033,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Inventiva (IVA) and Moderna (MRNA). Inventiva (IVA...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-inventiva-iva-and-moderna-mrna-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LGHT","MRNX","WDNA","BK4532","BK4551","XBI","BK4139","LU0128526141.USD","MRNA","BK4581","BK4137","LABU","IVA","BK4534","BK4568","XLV","BK4548","IDNA","BK4533","BK4501","MRNY","LU0029874061.USD","BK4588","HCSG","BK4585","GNOM"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1145285517","title":"Judge Rejects Pfizer, BioNTech, and Moderna Bid to Dismiss Monsanto mRNA Patent Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=1145285517","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1145285517?lang=en_us&edition=fundamental","pubTime":"2026-09-29 10:39","pubTimestamp":1790649592,"startTime":"0","endTime":"0","summary":"A federal judge in Delaware rejected a request on Monday from Pfizer (PFE.US), BioNTech (BNTX.US), and Moderna (MRNA.US) to dismiss a lawsuit brought against them by Monsanto, a unit of German...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4504","LU1074936037.SGD","FHLC","IE0034235303.USD","LU2430703095.HKD","LU0985320562.USD","IE00BJJMRZ35.SGD","IE00B1BXHZ80.USD","LGHT","LU0795875086.SGD","VHT","MRNX","LU0345770993.USD","LU0787776722.HKD","BK4568","LU0868494617.USD","LU2023250330.USD","LU1059921491.USD","LU2471134796.USD","LU0985481810.HKD","XLV","LU1732800096.USD","IHE","LU1043141396.HKD","LU1221951046.USD","PFE","LU2089984988.USD","IE00B3PB1722.GBP","LU0289739699.SGD","OZEM","LU0795875169.SGD","LU0466842654.USD","LU0124676726.USD","LU0072461881.USD","LU1003077747.HKD","LU0426417589.USD","LU0949170772.SGD","LU0640476718.USD","IE00B2B36J28.USD","LU0170899867.USD","LU0545562505.USD","LU1162221912.USD","LU0234570918.USD","LU0053666078.USD","LU1496350502.SGD","LU2471134523.USD","IE00BLSP4452.SGD","MRNY","BMED","LU0456855351.SGD","IE0002141913.USD","LU1551013342.USD","LU0098860793.USD","BK4551","LU0943347566.SGD","BK4501","LU0058720904.USD","LU1043141123.HKD","LU1778281490.HKD","IE00BN8TJ469.HKD","LU2471134879.HKD","RXL","LU1674673428.USD","LU1261432733.SGD","BNTX","LU1061106388.HKD","LU2129689605.HKD","LU2602419157.SGD","LU0472753341.HKD","LU0114720955.EUR","LU0321505439.SGD","LU0057025933.USD","LU0683600562.USD","LU1121112475.USD","LU1718418525.SGD","IE00B19Z3581.USD","IE00B7SZLL34.SGD","LU2896262040.SGD","LU1929549753.HKD","LU1244550221.USD","LU1291159041.SGD","LU1244550577.SGD","JNJ","LU2750360641.GBP","SG9999001176.SGD","IE00BFTCPJ56.SGD","LU0820561909.HKD","LU1894683348.USD","IE00B3T34201.USD","LU0882574055.USD","SG9999001440.SGD","IE00BZ1G4Q59.USD","LU1066053197.SGD","IE00BKVL7J92.USD","LU0792757196.USD","BK4585","LU1983299246.USD","LU0306806265.USD","MEDX","LU2756315318.SGD","IE000WAW04H5.SGD","TRUH","BK4533","LU1267930813.SGD","LU0210536198.USD","LU2750360997.AUD","LU0689626769.HKD","LU0820562030.AUD","SG9999001176.USD","LU2112291526.USD","LU0321505868.SGD","BK4534","IE00BFXG1179.USD","LU2430703178.SGD","IE000SO60NU8.SGD","IE00BVYPNV92.GBP","WDNA","IE0002270589.USD","IE00BGHQF631.EUR","BK4548","LU1883839398.USD","SG9999003800.SGD","SG9999011175.SGD","IE00B42XCP33.USD","LU0122379950.USD","LU1629891620.HKD","LU2133065610.SGD","LU1145028129.USD","IE00BDGV0183.EUR","LU1228905037.USD","LU1989771016.USD","IE0000B7K699.USD","LU2347655156.SGD","IE000F7OJYX1.SGD","IE000M9KFDE8.USD","LU0225771236.USD","LU2430703251.USD","LU1280957306.USD","IE000BZT7R73.USD","LU1228905540.USD","LU0225284248.USD","BAYRY","IE0001KFT4U8.USD","LU2505996509.AUD","LU1585245621.USD","LU1057294990.SGD","IE00B4R5TH58.HKD","SGXZ57979304.SGD","LU0345770308.USD","IE0009355771.USD","LU0689472784.USD","IE00B19Z3B42.SGD","IE00BBT3K403.USD","IE000MB6IJN5.SGD","LU0289961442.SGD","BK4592","FTXH","LU1551013425.SGD","LU0553294199.USD","IE00BVYPNW00.USD","BK4535","LU0162691827.USD","GDOC","LU0738911758.USD","LU0320765646.SGD","LU2129689514.USD","IE00BSNM7G36.USD","BK4139","LU2487616109.SGD","IYH","LU2213496289.HKD","LU2592432038.USD","LU2596442595.SGD","LU1032955483.USD","LU0234572021.USD","BK4588","LU0289739343.SGD","MRNA","LU1732799900.SGD","LU0545039389.USD","LU0820561818.USD","LU0210528500.USD","BK4532","LU1914381329.SGD","LU1244550494.USD","SG9999013999.USD","LU0306807586.USD","LU1674673691.USD","LU1935042991.SGD","IDNA","LU2456880835.USD","LU1221951129.SGD","LU0345769631.USD","LU0426412945.USD","LU2468319806.SGD","BK4007","IXJ","LU1023059063.AUD","LU1196500208.SGD","LU2403377893.USD","BK4559","LU1066051811.HKD","LU0889566641.SGD","PJP","LU1506573853.SGD","LU0203347892.USD","LU2471134952.CNY","JDOC","LU1430594728.SGD","LU1032466523.USD","IE00BLSP4239.USD","LU0069063385.USD","LU0964807845.USD","SG9999002224.SGD","LU0070217475.USD","LU0912757837.SGD","LU0203345920.USD","LU0432979614.USD","BK4599","LU2756315664.SGD","SG9999002232.USD","LU2129689431.USD","LU1066051498.USD","LU2236285917.USD","GNOM","LU0994945656.USD","LU1066051225.USD","LU0511384066.AUD","LU2417539215.USD","LU1894683264.USD","BK4550","BK4581","LU0661504455.SGD","IE00BJT1NW94.SGD","SGXZ80539844.SGD","LU2505996681.GBP","LU0345769128.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671086260","title":"How Investors May Respond To Pfizer (PFE) ESMO Cancer Data Showcase","url":"https://stock-news.laohu8.com/highlight/detail?id=2671086260","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671086260?lang=en_us&edition=fundamental","pubTime":"2026-09-29 09:19","pubTimestamp":1790644788,"startTime":"0","endTime":"0","summary":"Pfizer will showcase data from 45 oncology research abstracts at the October 2026 ESMO Congress in Madrid, including 11 oral presentations on established medicines such as PADCEV and TALZENNA, as well as late stage candidates like atirmociclib and tivunatamig.\nThe scale of Pfizer’s ESMO presence signals a strong R&D emphasis on cancer therapies at a time when the business is repositioning away from COVID products and facing pricing and competition pressure in other areas.\nWe will now look at...","market":"hk","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/162270-card/1788974859487","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/company-cover/162270-card/1788974859487"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/how-investors-may-respond-to-pfizer-pfe-esmo-cancer-data-sho","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-pfe/pfizer/news/how-investors-may-respond-to-pfizer-pfe-esmo-cancer-data-sho","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["LU0321505439.SGD","BK4581","BK4568","LU0456855351.SGD","LU0985481810.HKD","LU0225771236.USD","OZEM","LU1066051498.USD","PFE","SG9999011175.SGD","SG9999001176.SGD","LU1894683348.USD","SG9999002232.USD","IE00BLSP4452.SGD","IE00B19Z3581.USD","LU0306807586.USD","BK4585","BK4588","LU0225284248.USD","LU1023059063.AUD","LU1057294990.SGD","SG9999003800.SGD","IE00BLSP4239.USD","BK4533","LU0170899867.USD","LU0289739699.SGD","SG9999001176.USD","SG9999002224.SGD","LU0321505868.SGD","IE00B19Z3B42.SGD","LU2596442595.SGD","BK4534","IE0002270589.USD","BK4007","IE000M9KFDE8.USD","BK4599","LU1066053197.SGD","SGXZ57979304.SGD","LU0058720904.USD","LU1894683264.USD","BK4550","LU0234572021.USD","LU0122379950.USD","LU0306806265.USD","LU1883839398.USD","IE00BBT3K403.USD","IE00B3T34201.USD","LU0868494617.USD","SG9999013999.USD","BK4592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671666512","title":"Hutchmed says AstraZeneca submits NDA for ORPATHYS+TAGRISSO in NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2671666512","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671666512?lang=en_us&edition=fundamental","pubTime":"2026-09-29 08:06","pubTimestamp":1790640404,"startTime":"0","endTime":"0","summary":"Hutchmed (HCM) “announces that AstraZeneca (AZN) has submitted a New Drug Application to the US Food and Drug Administration for ORPATHYS (savoliti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/hutchmed-says-astrazeneca-submits-nda-for-orpathystagrisso-in-nsclc-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/hutchmed-says-astrazeneca-submits-nda-for-orpathystagrisso-in-nsclc-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0058720904.USD","LU0109394709.USD","LU2237443622.USD","LU2236285917.USD","BK4585","LU0029864427.USD","LU2237443465.HKD","LU0320765992.SGD","HCM","AZNH","IE00B3T34201.USD","BK4568","LU1829250122.USD","LU2237443549.SGD","BK4588","LU0432979614.USD","LU2468319806.SGD","LU2456880835.USD","LU2462157665.USD","LU0310800379.SGD","LU2089984988.USD","LU2417539215.USD","AZN","LU2237443978.SGD","LU1267930573.SGD","LU0708994859.HKD","LU0289739699.SGD","LU2237443382.USD","BK4007","BK4531","LU0889565916.HKD","LU0128525929.USD","LU2237443895.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671630272","title":"Stocks to Watch: Summit Therapeutics, Sangoma, Navitas","url":"https://stock-news.laohu8.com/highlight/detail?id=2671630272","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671630272?lang=en_us&edition=fundamental","pubTime":"2026-09-29 07:13","pubTimestamp":1790637180,"startTime":"0","endTime":"0","summary":"Summit Therapeutics is getting a $2 billion investment from AstraZeneca. The stock rose 17% to $18.08 in after-hours trading Monday.Sangoma Technologies is set to be acquired by BRC in a deal that values the company at $204 million. Shares climbed 39% to $4.98 after the bell.Navitas Semiconductor got an Army grant to develop semiconductor technology. The stock gained 14% to $13.40.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0029864427.USD","AZN","BK4588","AZNH","BK4139","LU2237443622.USD","NVTC","LU0109394709.USD","LU0128525929.USD","BK4585","NVTX","BK4141","LU2089984988.USD","LU0708994859.HKD","LU1267930573.SGD","LU1829250122.USD","LU2417539215.USD","LU2237443978.SGD","LU0320765992.SGD","LU2237443895.HKD","BK4568","LU2237443465.HKD","LU0889565916.HKD","LU0432979614.USD","LU2456880835.USD","LU0310800379.SGD","LU2468319806.SGD","LU2488822045.USD","SANG","BK4007","LU2237443382.USD","BK4020","LU0289739699.SGD","SMMT","LU2462157665.USD","IE00B3T34201.USD","LU0058720904.USD","LU2236285917.USD","NVTS","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671268214","title":"Nanoviricides Q4 EPS $(0.10), Inline","url":"https://stock-news.laohu8.com/highlight/detail?id=2671268214","media":"Benzinga Earnings","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671268214?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:47","pubTimestamp":1790632052,"startTime":"0","endTime":"0","summary":"Nanoviricides (AMEX:NNVC) reported quarterly losses of $(0.10) per share which met the analyst consensus estimate. This is a 23.08 percent increase over losses of $(0.13) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/62037224/nanoviricides-q4-eps-0-10-inline","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Nanoviricides Q4 EPS $(0.10), Inline","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NNVC","BK4568","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671680942","title":"Summit Therapeutics, AstraZeneca enter clinical collaboration agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2671680942","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671680942?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:40","pubTimestamp":1790631610,"startTime":"0","endTime":"0","summary":"Summit (SMMT) entered into a clinical collaboration agreement with AstraZeneca (AZN) to evaluate sonesitatug vedotin in combination with ivonescima...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-astrazeneca-enter-clinical-collaboration-agreement-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/summit-therapeutics-astrazeneca-enter-clinical-collaboration-agreement-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU2237443549.SGD","LU2237443622.USD","LU2488822045.USD","LU2417539215.USD","LU2089984988.USD","LU2456880835.USD","BK4007","AZNH","LU2236285917.USD","LU0029864427.USD","LU2237443382.USD","BK4588","LU0128525929.USD","SMMT","LU0708994859.HKD","LU2462157665.USD","LU0310800379.SGD","AZN","LU0109394709.USD","BK4585","BK4539","LU2468319806.SGD","LU2237443465.HKD","BK4568","BK4139","LU1267930573.SGD","LU0889565916.HKD","LENZ","LU0289739699.SGD","LU0320765992.SGD","IE00B3T34201.USD","LU0058720904.USD","LU1829250122.USD","LU2237443895.HKD","LU0432979614.USD","LU2237443978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671268184","title":"Novavax Inc. Stock Outperforms Competitors on Strong Trading Day","url":"https://stock-news.laohu8.com/highlight/detail?id=2671268184","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671268184?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:30","pubTimestamp":1790631000,"startTime":"0","endTime":"0","summary":"DJ Novavax Inc. Stock Outperforms Competitors On Strong Trading DayThis article was automatically generated by MarketWatch using technology from Automated Insights.Shares of Novavax Inc.  rose 1.60% to $10.80 Monday, on what proved to be an all-around rough trading session for the stock market, with the NASDAQ Composite Index  falling 0.92% to 26,820.38 and Dow Jones Industrial Average  falling 0.67% to 51,481.51.This was the stock's third consecutive day of gains.Novavax Inc. closed 9.77% below its 52-week high of $11.97, which the company reached on February 26th.The stock outperformed some of its competitors Monday, as Johnson & Johnson  rose 0.27% to $271.95, Pfizer Inc.  rose 0.17% to $28.72, and Merck & Co. Inc.  fell 0.06% to $148.69.Trading volume  remained 215,526 below its 50-day average volume of 4.7 M.Data source: Dow Jones Market Data, FactSet. Data compiled September 28, 2026.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4568","BK4585","BK4139","NVAX","BK4547"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671268309","title":"BioNTech CEO Uğur Şahin Disposes of USD 6,090,748 in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2671268309","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671268309?lang=en_us&edition=fundamental","pubTime":"2026-09-29 05:17","pubTimestamp":1790630234,"startTime":"0","endTime":"0","summary":"BioNTech CEO Uur ahin disposes of USD 6,090,748 in common sharesBioNTech CEO Ugur Sahin sold 61,000 ordinary shares on Sept. 25-28, filings show.Sales priced at USD 98.6882 to USD 98.4682 per share.Di","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL8jQYft:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"BioNTech CEO Uğur Şahin Disposes of USD 6,090,748 in Common Shares","news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4548","BK4585","BK4139","BK4535","BK4588","BK4568","BNTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671250558","title":"NanoViricides FY26 Net Loss Narrows 13% to $8.22 Million; Revenue Remains no Revenue","url":"https://stock-news.laohu8.com/highlight/detail?id=2671250558","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671250558?lang=en_us&edition=fundamental","pubTime":"2026-09-29 04:32","pubTimestamp":1790627535,"startTime":"0","endTime":"0","summary":"NanoViricides FY26 net loss narrows 13% to $8.22 million; revenue remains no revenueNanoViricides posted a net loss of $8.22 million for the year ended June 30, 2026, narrowing 13%.Basic and diluted l","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nNDL7KM1TX:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NNVC","BK4568"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671827252","title":"Pfizer, Moderna Lose Bids to Escape Bayer US mRNA Patent Lawsuit","url":"https://stock-news.laohu8.com/highlight/detail?id=2671827252","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671827252?lang=en_us&edition=fundamental","pubTime":"2026-09-29 02:20","pubTimestamp":1790619619,"startTime":"0","endTime":"0","summary":"Pfizer, Moderna lose bids to escape Bayer US mRNA patent lawsuitSept 28 (Reuters)-A federal judge in Delaware on Monday rejected PfizerPFE.N, BioNTech22UAy.DEand Moderna'sMRNA.Orequests to dismiss pat","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260928:nL6N45K0Z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BLSP4239.USD","IE00B3T34201.USD","LU1066053197.SGD","OZEM","LGHT","LU1023059063.AUD","BK4139","MRNA","MRNX","IE000M9KFDE8.USD","LU0122379950.USD","IE00BLSP4452.SGD","BK4551","SGXZ57979304.SGD","LU0306806265.USD","BNTX","LU0289739699.SGD","LU0321505868.SGD","BK4599","SG9999002224.SGD","SG9999002232.USD","BK4501","LU2596442595.SGD","SG9999001176.SGD","IE00B19Z3B42.SGD","MRNY","BK4007","BK4592","LU0225284248.USD","LU0225771236.USD","IE0002270589.USD","LU0306807586.USD","LU0321505439.SGD","LU0868494617.USD","SG9999013999.USD","BK4568","LU0058720904.USD","IE00BBT3K403.USD","LU1057294990.SGD","LU1883839398.USD","BK4550","LU0456855351.SGD","BK4535","BK4548","LU0985481810.HKD","BK4588","LU1894683264.USD","LU1066051498.USD","IDNA","LU1894683348.USD","WDNA","PFE","SG9999011175.SGD","SG9999003800.SGD","BK4533","IE00B19Z3581.USD","GNOM","BAYZF","BK4532","BK4581","BK4585","SG9999001176.USD","LU0234572021.USD","LU0170899867.USD","BK4534"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671504251","title":"Market Chatter: BioNTech to Close 3 German Sites After Unsuccessful Sale Efforts","url":"https://stock-news.laohu8.com/highlight/detail?id=2671504251","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671504251?lang=en_us&edition=fundamental","pubTime":"2026-09-29 00:42","pubTimestamp":1790613721,"startTime":"0","endTime":"0","summary":"BioNTech  is closing three German sites it failed to sell in a shift away from pandemic-era manufacturing, Reuters reported Monday, citing a company spokesperson.The company agreed with the works council on socially responsible solutions and supplementary redundancy for affected employees, the report said.BioNTech did not immediately respond to a request for comment from MT Newswires.Price: 99.12, Change: +0.60, Percent Change: +0.61","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4551","BK4548","BK4535","BK4588","BK4568","BNTX","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":14,"pageCount":12,"totalSize":279,"code":"91000000","status":"200"}]}}